Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

BACKGROUND: Studies that have reported lower risk for cardiovascular outcomes in users of Sodium–Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascular disease (CVD). This study compared risk of cardiovascular events in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Vistisen, Dorte, Carstensen, Bendix, Elisabetta, Patorno, Lanzinger, Stefanie, Tan, Elise Chia-Hui, Yabe, Daisuke, Kim, Dae Jung, Sheu, Wayne H.-H., Melzer-Cohen, Cheli, Holl, Reinhard W., Núñez, Júlio, Ha, Kyoung Hwa, Halvorsen, Sigrun, Langslet, Gisle, Karasik, Avraham, Nyström, Thomas, Niskanen, Leo, Guleria, Sonia, Klement, Riho, Carrasco, Marc, Foersch, Johannes, Shay, Christina, Koeneman, Lisette, Hoti, Fabian, Farsani, Soulmaz Fazeli, Khunti, Kamlesh, Zaccardi, Francesco, Subramanian, Anuradhaa, Nirantharakumar, Krishnarajah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472675/
https://www.ncbi.nlm.nih.gov/pubmed/37653496
http://dx.doi.org/10.1186/s12933-023-01963-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472675/
https://www.ncbi.nlm.nih.gov/pubmed/37653496
http://dx.doi.org/10.1186/s12933-023-01963-9

Ejemplares similares